FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978321773> ?p ?o ?g. }

• W1978321773 endingPage "27" @default.
• W1978321773 startingPage "19" @default.
• W1978321773 abstract "Proteins that undergo receptor-mediated endocytosis are subject to lysosomal degradation, requiring radioiodination methods that minimize loss of radioactivity from tumor cells after this process occurs. To accomplish this, we developed the residualizing radioiodination agent Nϵ-(3-[⁎I]iodobenzoyl)-Lys5-Nα-maleimido-Gly1-d-GEEEK (Mal-d-GEEEK-[⁎I]IB), which enhanced tumor uptake but also increased kidney activity and necessitates generation of sulfhydryl moieties on the protein. The purpose of the current study was to synthesize and evaluate a new d-amino acid based agent that might avoid these potential problems. Nα-(3-iodobenzoyl)-(5-succinimidyloxycarbonyl)-d-EEEG (NHS-IB-d-EEEG), which contains 3 d-glutamates to provide negative charge and a N-hydroxysuccinimide function to permit conjugation to unmodified proteins, and the corresponding tin precursor were produced by solid phase peptide synthesis and subsequent conjugation with appropriate reagents. Radioiodination of the anti-HER2 antibody trastuzumab using NHS-IB-d-EEEG and Mal-d-GEEEK-IB was compared. Paired-label internalization assays on BT474 breast carcinoma cells and biodistribution studies in athymic mice bearing BT474M1 xenografts were performed to evaluate the two radioiodinated d-peptide trastuzumab conjugates. NHS-[131I]IB-d-EEEG was produced in 53.8% ± 13.4% and conjugated to trastuzumab in 39.5% ± 7.6% yield. Paired-label internalization assays with trastuzumab-NHS-[131I]IB-d-EEEG and trastuzumab-Mal-d-GEEEK-[125I]IB demonstrated similar intracellular trapping for both conjugates at 1 h (131I, 84.4% ± 6.1%; 125I, 88.6% ± 5.2%) through 24 h (131I, 60.7% ± 6.8%; 125I, 64.9% ± 6.9%). In the biodistribution experiment, tumor uptake peaked at 48 h (trastuzumab-NHS-[131I]IB-d-EEEG, 29.8% ± 3.6%ID/g; trastuzumab-Mal-d-GEEEK-[125I]IB, 45.3% ± 5.3%ID/g) and was significantly higher for 125I at all time points. In general, normal tissue levels were lower for trastuzumab-NHS-[131I]IB-d-EEEG, with the differences being greatest in kidneys (131I, 2.2% ± 0.4%ID/g; 125I, 16.9% ± 2.8%ID/g at 144 h). NHS-[131I]IB-d-EEEG warrants further evaluation as a residualizing radioiodination agent for labeling internalizing antibodies/fragments, particularly for applications where excessive renal accumulation could be problematic." @default.
• W1978321773 created "2016-06-24" @default.
• W1978321773 creator A5003562375 @default.
• W1978321773 creator A5004932593 @default.
• W1978321773 creator A5045964365 @default.
• W1978321773 creator A5051030085 @default.
• W1978321773 creator A5058795170 @default.
• W1978321773 date "2015-01-01" @default.
• W1978321773 modified "2023-10-17" @default.
• W1978321773 title "D-amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination" @default.
• W1978321773 cites W1968885065 @default.
• W1978321773 cites W1969275840 @default.
• W1978321773 cites W1977290575 @default.
• W1978321773 cites W1982322665 @default.
• W1978321773 cites W1985114029 @default.
• W1978321773 cites W1994342180 @default.
• W1978321773 cites W1996060454 @default.
• W1978321773 cites W2015153696 @default.
• W1978321773 cites W2019492358 @default.
• W1978321773 cites W2030994818 @default.
• W1978321773 cites W2037586021 @default.
• W1978321773 cites W2040087569 @default.
• W1978321773 cites W2054706573 @default.
• W1978321773 cites W2060336217 @default.
• W1978321773 cites W2066618419 @default.
• W1978321773 cites W206963652 @default.
• W1978321773 cites W2078305838 @default.
• W1978321773 cites W2079432750 @default.
• W1978321773 cites W2080134708 @default.
• W1978321773 cites W2083666292 @default.
• W1978321773 cites W2084687819 @default.
• W1978321773 cites W2111965158 @default.
• W1978321773 cites W2125628845 @default.
• W1978321773 cites W2126375207 @default.
• W1978321773 cites W2126831997 @default.
• W1978321773 cites W2130870133 @default.
• W1978321773 cites W2135593703 @default.
• W1978321773 cites W2137076998 @default.
• W1978321773 cites W2141346487 @default.
• W1978321773 cites W2151425644 @default.
• W1978321773 cites W2166018412 @default.
• W1978321773 cites W2170241131 @default.
• W1978321773 cites W2732122454 @default.
• W1978321773 cites W2952828878 @default.
• W1978321773 doi "https://doi.org/10.1016/j.nucmedbio.2014.08.007" @default.
• W1978321773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4268387" @default.
• W1978321773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25240914" @default.
• W1978321773 hasPublicationYear "2015" @default.
• W1978321773 type Work @default.
• W1978321773 sameAs 1978321773 @default.
• W1978321773 citedByCount "9" @default.
• W1978321773 countsByYear W19783217732018 @default.
• W1978321773 countsByYear W19783217732019 @default.
• W1978321773 countsByYear W19783217732020 @default.
• W1978321773 countsByYear W19783217732021 @default.
• W1978321773 countsByYear W19783217732022 @default.
• W1978321773 crossrefType "journal-article" @default.
• W1978321773 hasAuthorship W1978321773A5003562375 @default.
• W1978321773 hasAuthorship W1978321773A5004932593 @default.
• W1978321773 hasAuthorship W1978321773A5045964365 @default.
• W1978321773 hasAuthorship W1978321773A5051030085 @default.
• W1978321773 hasAuthorship W1978321773A5058795170 @default.
• W1978321773 hasBestOaLocation W19783217732 @default.
• W1978321773 hasConcept C112613896 @default.
• W1978321773 hasConcept C121608353 @default.
• W1978321773 hasConcept C126322002 @default.
• W1978321773 hasConcept C134306372 @default.
• W1978321773 hasConcept C139770010 @default.
• W1978321773 hasConcept C170493617 @default.
• W1978321773 hasConcept C178790620 @default.
• W1978321773 hasConcept C185592680 @default.
• W1978321773 hasConcept C197336794 @default.
• W1978321773 hasConcept C202751555 @default.
• W1978321773 hasConcept C21951064 @default.
• W1978321773 hasConcept C2777807558 @default.
• W1978321773 hasConcept C2779281246 @default.
• W1978321773 hasConcept C2779786085 @default.
• W1978321773 hasConcept C2779809887 @default.
• W1978321773 hasConcept C28005876 @default.
• W1978321773 hasConcept C33923547 @default.
• W1978321773 hasConcept C40875361 @default.
• W1978321773 hasConcept C515207424 @default.
• W1978321773 hasConcept C521977710 @default.
• W1978321773 hasConcept C530470458 @default.
• W1978321773 hasConcept C55493867 @default.
• W1978321773 hasConcept C71924100 @default.
• W1978321773 hasConceptScore W1978321773C112613896 @default.
• W1978321773 hasConceptScore W1978321773C121608353 @default.
• W1978321773 hasConceptScore W1978321773C126322002 @default.
• W1978321773 hasConceptScore W1978321773C134306372 @default.
• W1978321773 hasConceptScore W1978321773C139770010 @default.
• W1978321773 hasConceptScore W1978321773C170493617 @default.
• W1978321773 hasConceptScore W1978321773C178790620 @default.
• W1978321773 hasConceptScore W1978321773C185592680 @default.
• W1978321773 hasConceptScore W1978321773C197336794 @default.
• W1978321773 hasConceptScore W1978321773C202751555 @default.
• W1978321773 hasConceptScore W1978321773C21951064 @default.
• W1978321773 hasConceptScore W1978321773C2777807558 @default.

• next